EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Coden USA: EJBPBO
Volume: 13
Issue: 5
Year: 2026

OXIDATIVE STRESS AND LIVER DISORDERS: ROLE OF NATURAL ANTIOXIDANTS WITH EMPHASIS ON COCOA BIOACTIVES

***Sonali Sharma, Dr. Sagarika Kabra, Ms. Geetika Mehta, Ghanshyam, Abhishek Saini, Ms. Anjali Singh, Ms. Rashmi Tripathi, Dr. Monika Sachdeva**

[1-6]Raj Kumar Goel Institute of Technology (Pharmacy), 5-Km. Stone, Delhi-Meerut Road, Ghaziabad, Uttar Pradesh 201017, India.

***Corresponding Author: Sonali Sharma**

Raj Kumar Goel Institute of Technology (Pharmacy), 5-Km. Stone, Delhi-Meerut Road, Ghaziabad, Uttar Pradesh 201017, India.

DOI: https://doi.org/10.5281/zenodo.19908057

How to cite this Article: *Sonali Sharma, Dr. Sagarika Kabra, Ms. Geetika Mehta, Ghanshyam, Abhishek Saini, Ms. Anjali Singh, Ms. Rashmi Tripathi, Dr. Monika Sachdeva. (2026). Oxidative Stress And Liver Disorders: Role Of Natural Antioxidants With Emphasis On Cocoa Bioactives. European Journal of Biomedical and Pharmaceutical Sciences, 13(5), 80–92.


This work is licensed under Creative Commons Attribution 4.0 International license.

Article Received on 05/04/2026 **Article Revised on 25/04/2026** **Article Published on 01/05/2026**

ABSTRACT

The pathophysiology and development of a number of liver diseases, including as alcoholic liver disease, viral hepatitis, drug-induced hepatotoxicity, liver fibrosis, and non-alcoholic fatty liver disease (NAFLD), are significantly influenced by oxidative stress. Overproduction of reactive oxygen species (ROS) throws off the cellular redox equilibrium, resulting in inflammation, hepatocellular damage, lipid peroxidation, and mitochondrial dysfunction. While traditional pharmacotherapy can alleviate symptoms, it frequently falls short in addressing oxidative damage and can have negative side effects. Consequently, natural antioxidants have drawn more interest as possible hepatoprotective agents. This study assesses the therapeutic potential of natural antioxidants, with a focus on cocoa bioactives, and highlights the most recent data about the role of oxidative stress in liver illnesses. For papers published between 2000 and 2025, a thorough literature search was carried out using PubMed, Scopus, Web of Science, and Google Scholar. Included were preclinical, clinical, and experimental research on antioxidant-mediated hepatoprotection. Natural antioxidants have been shown to reduce liver damage by scavenging free radicals, improving endogenous antioxidant enzymes (catalase, glutathione peroxidase, and superoxide dismutase), modifying inflammatory pathways, and lowering fibrosis. In experimental models of liver damage, cocoa bioactives particularly flavonoids like epicatechin, catechin, and procyanidins show notable lipid-modulating, anti-inflammatory, and antioxidant properties. All things considered, polyphenols produced from cocoa are intriguing nutraceutical candidates for treating liver illnesses caused by oxidative stress; nonetheless, extensive clinical research are required to verify their safety, effectiveness, and ideal therapeutic dosage.

KEYWORDS: Oxidative stress; Liver disorders; Natural antioxidants; Cocoa bioactives; Flavonoids; Hepatoprotection; Reactive oxygen species (ROS).



1. INTRODUCTION

Considering they are responsible for a significant amount of premature mortality and disability-adjusted life years (DALYs) globally, liver diseases represent a significant public health problem. Recent estimates from throughout the world indicate that liver disorders together cause around 2 million fatalities a year, or roughly 3–4% of all deaths worldwide. Given their substantial socioeconomic burden, chronic liver disorders and cirrhosis are among the top causes of death for persons between the ages of 30 and 70.[1] The most common chronic liver illness is non-alcoholic fatty liver disease (NAFLD), which affects 25–30% of adults worldwide. Obesity, type 2 diabetes, and metabolic syndrome are associated with greater prevalence rates of NAFLD.[2] Due to fast urbanization, sedentary lifestyles, and dietary changes, the burden is especially growing in emerging nations. Nearly 20–30% of people with NAFLD may develop non-alcoholic steatohepatitis (NASH), which raises the risk of cirrhosis, fibrosis, and hepatocellular carcinoma (HCC) considerably.[3]

A significant amount of cirrhosis cases globally are caused by alcoholic liver disease, which is still a leading cause of liver-related death. With more than 250 million individuals worldwide suffering from chronic hepatitis B virus (HBV) and 50-60 million from hepatitis C virus (HCV), viral hepatitis continues to be a serious problem. It causes gradual liver damage and raises the risk of cancer. Additionally, in many nations, one of the main causes of abrupt liver failure is drug-induced liver damage (DILI).[4] Hepatic illnesses that proceed silently from steatosis to cirrhosis, fibrosis, and ultimately liver failure or cancer may take longer to diagnose until they are at an advanced stage. When taken as a whole, these disorders have a substantial clinical, financial, and medical impact, highlighting the urgent need for therapeutic and preventative approaches that focus on important pathogenic processes including oxidative stress.[5]

1.1. Oxidative Stress as a Central Pathogenic Mechanism

It is commonly acknowledged that oxidative stress is a major molecular mechanism that underlies the development and progression of liver diseases. It is caused by an imbalance between the antioxidant defense system and the generation of reactive oxygen species (ROS). Environmental pollutants, inflammatory cell infiltration, cytochrome P450 enzyme activity, and mitochondrial malfunction all contribute to the overproduction of ROS in hepatocytes.[6] Lipid peroxidation, protein oxidation, DNA damage, and the activation of redox-sensitive transcription factors like Nrf2 and NF-κB are all caused by elevated ROS levels.[7] Hepatic tissue eventually becomes structurally and functionally impaired as a result of these molecular processes, which also stimulate fibrogenesis, apoptosis, stellate cell activation, and inflammation. Targeting oxidative stress has therefore emerged as a potentially effective treatment strategy for both preventing and delaying the development of liver disorders.[8]

1.2. Importance of Natural Antioxidants

As a result of their capacity to reduce inflammation, boost endogenous antioxidant enzymes, and neutralize free radicals, natural antioxidants have drawn a lot of interest. Bioactive substances originating from plants, including polyphenols, flavonoids, carotenoids, and vitamins, have potent cytoprotective and free radical scavenging capabilities.[9] Natural substances are typically linked to improved safety profiles and extra pharmacological advantages, such as lipid-lowering, anti-inflammatory, and antifibrotic activities, in contrast to manufactured antioxidants.[10] Natural antioxidants may reduce oxidative liver damage by reestablishing redox equilibrium and enhancing mitochondrial activity, according to a number of preclinical and clinical investigations. As a result, more research is being done on nutraceutical-based therapies as preventative or supplemental measures for hepatic diseases.[11]

1.3. Justification for Focusing on Cocoa Bioactives

Cocoa (Theobroma cacao) is one of the natural sources that is most abundant in polyphenolic chemicals, notably flavanols like epicatechin, catechin, and procyanidins. The antioxidant potential of cocoa bioactives has been shown to be strong, surpassing that of several regularly ingested plant items. According to experimental research, cocoa flavonoids enhance endothelial and mitochondrial function, control lipid metabolism, inhibit inflammatory cytokines, and modify oxidative stress indicators.[12] These bioactives may have protective benefits against hepatic fibrosis, inflammation, and steatosis, according to new research. Cocoa-derived polyphenols are intriguing options for hepatoprotection because of their multifunctional pharmacological effects, safety profile, and absorption. Nevertheless, a thorough assessment of their molecular function in liver diseases brought on by oxidative stress is still required.[13]

2. OXIDATIVE STRESS AND MOLECULAR MECHANISMS IN LIVER DISORDERS

One of the main causes of the development and advancement of both acute and chronic liver disorders is oxidative stress. It results from an imbalance between the body's natural antioxidant defense mechanisms and the production of reactive oxygen species (ROS). Persistent oxidative stress encourages inflammation, fibrogenesis, carcinogenesis, and cellular damage in hepatic tissue.[15]

2.1. Generation of Reactive Oxygen Species (ROS)

ROS are produced in the liver from a variety of external and intracellular sources. The main source is the mitochondria, where superoxide anion ($O_2^{\bullet -}$) is formed by electron leakage from complexes I and III of the electron transport chain. When compared to healthy levels, mitochondrial ROS generation may rise two to three times in pathological circumstances such alcoholic liver disease and nonalcoholic fatty liver disease.[16]

CYP2E1 and other cytochrome P450 enzymes play a significant role in the production of ROS during drug biotransformation and alcohol metabolism. Furthermore, during inflammatory reactions, ROS are produced by invading neutrophils and activated Kupffer cells via NADPH oxidase.[17] Oxidative load is further enhanced by xanthine oxidase activity and peroxisomal β-oxidation.

2.2. Lipid Peroxidation, Protein Oxidation, and DNA Damage

Excess ROS cause polyunsaturated fatty acids in hepatocyte membranes to undergo lipid peroxidation, which produces the biomarkers of oxidative damage malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE). Patients with cirrhosis and NAFLD have been repeatedly found to have elevated hepatic MDA levels.[18] Lipid peroxidation damages membrane-bound enzymes, increases permeability, and compromises membrane integrity. Additionally, ROS cause protein oxidation, which leads to the production of carbonyls, changes in enzyme function, and proteasomal breakdown.[19] Hepatocyte dysfunction is accelerated and ATP generation is hindered by oxidative alteration of mitochondrial proteins. Additionally, oxidative DNA damage brought on by ROS results in the production of 8-hydroxy-2′-deoxyguanosine (8-OHdG), which has been observed to be higher in hepatocellular carcinoma and chronic hepatitis. Mutagenesis and malignant transformation are facilitated by accumulated DNA damage.[20]

2.3. Mitochondrial Dysfunction

Oxidative stress is both a cause and an effect of mitochondrial dysfunction. ATP depletion results from ROS-induced damage to respiratory chain complexes and mitochondrial DNA (mtDNA), which lowers the efficacy of oxidative phosphorylation. Steatosis is made worse by impaired β-oxidation, which causes lipid buildup in hepatocytes.[21] Cytochrome c release is encouraged by increased mitochondrial permeability transition pore (mPTP) opening, which sets off apoptotic cascades. Research shows that the severity of NASH and the advancement of fibrosis are substantially correlated with mitochondrial dysfunction.[22]

2.4. Redox-Sensitive Signaling Pathways

Numerous redox-sensitive transcription factors and signaling cascades that control inflammation, cell survival, and fibrosis are activated by oxidative stress.

- **NF-κB Pathway:** One important transcription factor that is triggered by ROS and pro-inflammatory stimuli is nuclear factor-kappa B (NF-κB).[23] IκB is phosphorylated and degraded by ROS, which causes NF-κB to move nuclearly and promotes the production of inflammatory cytokines such TNF-α, IL-1β, and IL-6. By inducing hepatic stellate cells, persistent NF-κB activation promotes fibrogenesis and maintains chronic hepatic inflammation.[24]
- **Nrf2/ARE Pathway:** One important cytoprotective mechanism against oxidative stress is the nuclear factor erythroid 2–related factor 2 (Nrf2) pathway.[25] Nrf2 is linked to Keap1 at rest and is intended to be degraded. Nrf2 dissociates and moves to the nucleus during oxidative stress, where it binds to antioxidant response elements (ARE) to activate genes that encode heme oxygenase-1 (HO-1), glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD). Advanced liver illnesses have been found to have impaired Nrf2 signaling, which lowers the body's ability to defend against free radicals.[26]
- **MAPK Pathway:** Oxidative stress triggers the activation of mitogen-activated protein kinases (MAPKs), such as p38, JNK, and ERK. Hepatocyte apoptosis and inflammation are significantly influenced by JNK activation in particular. Steatosis progression to steatohepatitis and fibrosis has been linked to sustained JNK signalling.[27]

Table 1: Redox-Sensitive Signalling Pathways in Oxidative Stress–Mediated Liver Injury.

Signalling Pathway	Key Components	Mechanism of Activation	Major Target Genes / Mediators	Role in Liver Disorders
NF-κB Pathway	NF-κB (p65/p50), IκB, IKK complex	ROS induce phosphorylation and degradation of IκB via IKK activation, allowing NF-κB translocation into the nucleus	TNF-α, IL-1β, IL-6, COX-2, iNOS	Promotes hepatic inflammation, cytokine production, Kupffer cell activation, and hepatic stellate cell stimulation leading to fibrosis.[28]
Nrf2/ARE Pathway	Nrf2, Keap1, ARE	Oxidative stress disrupts Nrf2–Keap1 complex; Nrf2 translocates to nucleus and binds ARE sequences	SOD, CAT, GPx, HO-1, NQO1, GCLC	Enhances antioxidant defense, restores redox balance, protects against hepatocyte injury; impaired signaling associated with disease progression.[29]
MAPK Pathway	ERK, JNK, p38 MAPK	ROS activate upstream kinases (MAPKKK → MAPKK → MAPK cascade) leading to phosphorylation of MAPKs	AP-1, c-Jun, pro-apoptotic proteins (Bax), inflammatory mediators	Regulates apoptosis, inflammation, and fibrogenesis; sustained JNK activation contributes to steatohepatitis and fibrosis.[30]

2.5. Role in Inflammation and Apoptosis

By triggering Kupffer cells and encouraging the production of cytokines, oxidative stress intensifies inflammatory reactions. Additionally, ROS increase the signaling of transforming growth factor-beta (TGF-β), which in turn promotes the activation of hepatic stellate cells and the deposition of extracellular matrix, ultimately resulting in fibrosis. Both internal (mitochondrial) and extrinsic mechanisms cause apoptosis. Oxidative liver damage models frequently show increased cytochrome c release, caspase-3 activation, and the Bax/Bcl-2 ratio.[31]

All of these biological processes lipid peroxidation, mitochondrial dysfunction, inflammatory signaling, and apoptotic pathways are coordinated by oxidative stress. These processes emphasize its pivotal function in the etiology and development of hepatic diseases, underscoring the potential therapeutic benefits of antioxidant-based therapies.




Fig. 1: The Role of Oxidative Stress and Antioxidants in Liver Diseases.[32]

3. OXIDATIVE STRESS IN MAJOR LIVER DISEASES

The pathophysiology and development of several acute and chronic liver illnesses are significantly influenced by oxidative stress. In many liver disease etiologies, hepatocellular damage, inflammation, and fibrogenesis are caused by excessive production of reactive oxygen species (ROS) and compromised antioxidant defences.[33]

3.1. Non-Alcoholic Fatty Liver Disease (NAFLD)

Type 2 diabetes mellitus, obesity, insulin resistance, and metabolic syndrome are all closely linked to non-alcoholic fatty liver disease (NAFLD). Its development is explained by the "multiple-hit hypothesis," which holds that hepatocytes become more susceptible to oxidative stress, inflammatory cytokines, and mitochondrial dysfunction as a result of lipid buildup (steatosis).[34]

Excessive ROS generation is a result of mitochondrial overload and elevated free fatty acid oxidation in NAFLD. Malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), two lipid peroxidation products, are markedly increased in non-alcoholic steatohepatitis (NASH) patients. Oxidative stress promotes inflammation and hepatocyte death by activating the JNK and NF-κB signaling pathways. The production of antioxidant enzymes is further decreased by impaired Nrf2 signaling, which exacerbates the course of the illness from basic steatosis to fibrosis.[35]

3.2. Alcoholic Liver Disease (ALD)

Chronic ethanol intake causes oxidative stress mainly via metabolism mediated by cytochrome P450 2E1 (CYP2E1), which leads to alcoholic liver disease. Acetaldehyde and ROS are produced during ethanol oxidation, which causes mitochondrial dysfunction and glutathione (GSH) depletion.[36]

Patients with ALD have higher levels of oxidative biomarkers, such as MDA and protein carbonyls. ROS exacerbate hepatocellular damage by activating Kupffer cells and elevating pro-inflammatory cytokines like TNF-α. Chronic oxidative damage contributes to cirrhosis and fibrosis by encouraging the activation of stellate cells and the deposition of extracellular matrix. Hepatic function is further compromised by ATP depletion and mitochondrial DNA damage.[37]

3.3. Viral Hepatitis

Chronic viral hepatitis, especially hepatitis B and C infections, is intimately associated with liver damage caused by oxidative stress. Viral proteins increase the production of ROS and directly disrupt mitochondrial

function. For instance, hepatitis C virus (HCV) core protein induces oxidative stress by disrupting electron transport chain activity.[38] Infected individuals have been shown to have elevated levels of oxidative DNA damage indicators, including 8-hydroxy-2′-deoxyguanosine (8-OHdG). Chronic oxidative stress speeds up fibrosis and maintains inflammatory reactions. This long-term oxidative environment raises the risk of hepatocellular carcinoma (HCC) and causes genetic instability.[39]

3.4. Drug-Induced Liver Injury (DILI)

One of the main causes of acute liver failure is drug-induced liver injury. Acetaminophen (paracetamol) is one of several hepatotoxic medications that produce harmful metabolites that cause an excessive amount of ROS. The reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) depletes hepatic glutathione in acetaminophen toxicity, resulting in mitochondrial dysfunction and oxidative damage.[40]

Lipid peroxidation, ATP depletion, and necrotic cell death are the outcomes of oxidative stress in DILI. Hepatocyte damage is further exacerbated by JNK activation and the mitochondrial permeability shift. One of the main contributing factors to the severity of drug-induced hepatotoxicity is antioxidant depletion.[41]

3.5. Liver Fibrosis and Hepatocellular Carcinoma (HCC)

One of the main causes of liver fibrosis is ongoing oxidative stress, which is indicated by an overabundance of extracellular matrix protein deposition. ROS stimulate collagen production and fibrogenesis by activating hepatic stellate cells via the TGF-β and NF-κB signaling pathways.[42]

Hepatocellular carcinoma develops in advanced stages as a result of mutagenesis and oncogenic transformation brought on by persistent oxidative DNA damage. Patients with HCC are regularly shown to have compromised antioxidant defense mechanisms and elevated oxidative indicators. Together, mitochondrial dysfunction, genetic instability, and persistent inflammatory signaling promote the development and spread of tumors.[43]

4. NATURAL ANTIOXIDANTS AS HEPATOPROTECTIVE AGENTS

Targeting redox imbalance has become a logical therapeutic approach as oxidative stress is a key mediator in the pathophysiology of liver illnesses. Because of their multitargeted molecular activities, natural antioxidants, especially phytochemicals derived from plants, have shown strong hepatoprotective potential. Natural antioxidants offer more extensive therapeutic advantages with generally positive safety profiles by concurrently modulating several signaling pathways, in contrast to traditional single-target medications.[44]

4.1. Classification of Natural Antioxidants

Natural antioxidants are broadly categorized based on their chemical structure and biological function:

- **Polyphenols:** Multiple hydroxyl groups joined to aromatic rings define polyphenols, which are secondary plant metabolites. They consist of tannins, lignans, stilbenes, and phenolic acids (gallic and caffeic acids). Their capacity to bind transition metals (Fe^{2+} , Cu^{2+}), contribute hydrogen atoms, and stabilize free radicals via resonance structures is what gives them their antioxidant potential. In experimental models of liver damage, polyphenols have demonstrated a 30–60% reduction in hepatic lipid peroxidation.[45]
- **Flavonoids:** Flavonoids, which are further subdivided into flavonols, flavanols, flavones, flavanones, anthocyanins, and isoflavones, constitute a significant subclass of polyphenols. Antioxidant capability is increased by structural elements like the double bond between C2 and C3 and the catechol group in the B ring. Flavonoids influence intracellular signaling cascades implicated in inflammation and death in addition to their direct scavenging of radicals.[46]
- **Vitamins:** Ascorbic acid, or vitamin C, is a water-soluble antioxidant that replenishes damaged vitamin E and lowers hydroxyl and superoxide radicals.[47] Vitamin E, also known as α-tocopherol, is a lipid-soluble antioxidant that stops cellular membrane lipid peroxidation chain reactions. Carotenoids (lycopene, β-carotene): Prevent oxidative membrane damage and quench singlet oxygen. Vitamin E administration has been shown to enhance blood transaminase levels and lower oxidative biomarkers in NAFLD patients, according to clinical research.[48]
- Minerals: Antioxidant enzymes require trace elements including manganese, copper, zinc, and selenium as vital cofactors. For instance: Glutathione peroxidase (GPx) activity requires selenium. Copper and zinc are parts of the enzyme superoxide dismutase (SOD). Increased vulnerability to oxidative liver damage is often linked to deficiencies in certain micronutrients.[49]

4.2. Molecular Mechanisms of Hepatoprotection

Natural antioxidants exert hepatoprotective effects through interconnected molecular mechanisms:

- **Free Radical Scavenging and Lipid Peroxidation Inhibition**: By giving electrons or hydrogen atoms to ROS, natural antioxidants neutralize them and stop the chain reactions that cause lipid peroxidation. This lessens the production of dangerous aldehydes such 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA). Hepatic MDA levels significantly decrease after antioxidant therapy in experimental models of CCl_4 -induced hepatotoxicity.[50]
- **Enhanced Endogenous Antioxidant Defense:** A variety of phytochemicals trigger the Nrf2/ARE

pathway, which results in the transcriptional upregulation of cytoprotective enzymes, including glutathione peroxidase (GPx), heme oxygenase-1 (HO-1), superoxide dismutase (SOD), catalase (CAT), and glutathione-S-transferase (GST).[51] This restores redox equilibrium and raises intracellular glutathione (GSH) levels. Research indicates that in oxidative damage models, antioxidant treatment can raise the amount of GSH in the liver by 20–50%.[52]

- **Anti-Inflammatory Modulation:** There is a tight relationship between inflammation and oxidative stress. Natural antioxidants decrease the synthesis of inflammatory mediators such TNF-α, IL-1β, IL-6, COX-2, and iNOS by blocking the activation of the NF-κB, MAPK, and JNK pathways. The hepatic inflammatory load is further decreased by inhibiting Kupffer cell activation.[53]
- **Anti-Apoptotic Effects:** Antioxidants prevent mitochondrial membrane depolarization, suppress caspase-3 activation, and modify the Bax/Bcl-2 ratio to control apoptosis. This shields hepatocytes from viral hepatitis and DILI, which are diseases that cause programmed cell death.[54]
- **Anti-Fibrotic Activity:** Hepatic stellate cells (HSCs) are activated by prolonged oxidative stress, which results in collagen deposition and fibrosis. Natural antioxidants inhibit the buildup of extracellular matrix by suppressing TGF-β/Smad signaling and reducing the production of α-smooth muscle actin (α-SMA). There is experimental evidence that antioxidant supplementation results in better histology and decreased collagen content.[55]
- **Enhancement of Mitochondrial Function:** Some phytochemicals stabilize electron transport chain complexes, promote mitochondrial biogenesis, and lower the production of ROS in the mitochondria. Hepatocellular integrity is preserved by enhanced ATP production and decreased mitochondrial permeability transition.[56]

Table 2: Molecular Mechanisms of Hepatoprotection by Natural Antioxidants.

Mechanism	Molecular Targets/Pathways	Effects on Liver Tissue
Free Radical Scavenging	ROS (O_2 $\bullet^-$, •OH, H_2 O_2); lipid radicals	Decreased MDA and 4-HNE levels; inhibition of lipid peroxidation; preservation of membrane integrity.[57]
Enhancement of Endogenous Antioxidant Defense	Nrf2/ARE pathway; SOD, CAT, GPx, HO-1, GST; GSH	Increased antioxidant enzyme expression; restoration of redox balance; 20–50% rise in hepatic GSH in experimental models
Anti-Inflammatory Modulation	NF-κB, MAPK, JNK pathways; TNF-α, IL-1β, IL-6, COX-2, iNOS	Reduced cytokine production; decreased Kupffer cell activation; attenuation of hepatic inflammation.[58]
Anti-Apoptotic Effects	Bax/Bcl-2 ratio; Caspase-3; mitochondrial membrane potential	Prevention of mitochondrial depolarization; reduced hepatocyte apoptosis
Anti-Fibrotic Activity	TGF-β/Smad pathway; α-SMA; hepatic stellate cells	Reduced collagen deposition; decreased extracellular matrix accumulation; improved histopathology
Improvement of Mitochondrial Function	Electron transport chain; ATP synthesis; mitochondrial permeability transition pore	Reduced mitochondrial ROS; enhanced ATP production; improved hepatocyte survival.[59]

4.3. Important Natural Antioxidants in Hepatoprotection

- **Silymarin:** The main active ingredient of silymarin, which is derived from milk thistle, is silibinin. It reduces lipid peroxidation, raises intracellular glutathione levels, and stabilizes hepatocyte membranes. Serum ALT and AST levels in individuals with chronic liver disease have improved, according to clinical research.[60]
- **Curcumin:** Curcumin has strong anti-inflammatory, anti-fibrotic, and antioxidant qualities. It decreases TGF-β-mediated stellate cell activation, inhibits NF-κB, and activates Nrf2. Steatosis and fibrosis are attenuated in NAFLD models, according to preclinical research.[61]
- **Resveratrol:** Resveratrol activates the AMPK and SIRT1 pathways, which improves mitochondrial activity. In fatty liver disease, it enhances insulin sensitivity and lowers oxidative stress indicators.[62]
- **Quercetin:** Because of its catechol structure, quercetin has a potent ability to scavenge free radicals. It guards against hepatotoxicity brought on by drugs and alcohol and inhibits pro-inflammatory cytokines.[63]

5. THEOBROMA CACAO BIOACTIVES AND HEPATOPROTECTIVE POTENTIAL

Theobroma cacao seeds are used to make cocoa, which is becoming more and more known as a functional dietary ingredient and a source of strong hepatoprotective phytochemicals. Being the main organ involved in the metabolism and detoxification of xenobiotics, the liver is especially susceptible to damage caused by oxidative stress.[64] By regulating redox balance, inflammatory cascades, mitochondrial

integrity, and fibrogenic signaling, cocoa bioactives provide a variety of protective benefits. Its function in reducing liver damage linked to metabolic syndrome, alcohol toxicity, drug exposure, and chronic inflammatory diseases is supported by new experimental and clinical data.[65]

5.1. Phytochemical Composition

Cocoa's strong polyphenolic composition is primarily responsible for its hepatoprotective properties. Flavanols, especially (-)-epicatechin and (+)-catechin, are found in remarkably high concentrations in cocoa beans; in unprocessed beans, they can make up as much as 10–15% of the dry weight. These monomeric flavanols have a potent antioxidant activity and are physiologically active. Cocoa is rich in oligomeric and polymeric procyanidins, which are condensed tannins made of flavanol units, in addition to monomers.[66] Procyanidins are known to have systemic metabolic and circulatory effects and to contribute considerably to overall antioxidant capacity. Approximately 1–4% of cocoa solids include the methylxanthine alkaloid theobromine, another significant bioactive.[67]

Theobromine has vasodilatory, anti-inflammatory, and moderate diuretic qualities, which indirectly improve hepatic microcirculation and metabolic function, while being less effective than coffee in stimulating the central nervous system. Additionally, cocoa includes phenolic acids that aid in metal-chelating and radical scavenging, including gallic acid, caffeic acid, and ferulic acid. Its biological profile is further enhanced by minor ingredients including dietary fiber and minerals (zinc, copper, and magnesium).[68]

The polyphenol concentration of cocoa is greatly influenced by its processing (alkalization, roasting, and fermentation). When assessing hepatoprotective effectiveness, processing conditions are crucial because natural, lightly processed cocoa retains higher quantities of flavanols than commercial goods that are excessively alkalized.[69]




Fig. 2: Major Phytochemical Composition of Theobroma Cacao.[70]

Table 3: Cocoa Bioactives and Their Role in Major Liver Disorders.

Cocoa Bioactive	NAFLD	ALD	DILI	Liver Fibrosis
Epicatechin	Improves insulin sensitivity; reduces hepatic triglyceride accumulation; activates Nrf2 and enhances SOD, CAT, GPx	Reduces ethanol-induced ROS; protects mitochondrial membrane potential; lowers TNF-α	Attenuates acetaminophen-induced oxidative stress; restores glutathione (GSH)	Inhibits hepatic stellate cell (HSC) activation; reduces collagen deposition[71]

Catechin	Decreases lipid peroxidation (↓MDA); modulates lipid metabolism genes (↓SREBP-1c)	Suppresses NF-κB activation; decreases inflammatory cytokines	Reduces ALT/AST elevation in toxic injury models	Downregulates TGF-β signaling; prevents extracellular matrix accumulation
Procyanidins	Strong antioxidant capacity; improves hepatic lipid oxidation	Prevents alcohol-mediated mitochondrial dysfunction	Chelates metal ions; reduces oxidative damage from drug metabolites	Inhibits fibrogenic cytokines; limits oxidative activation of HSCs[72]
Theobromine	Enhances hepatic blood flow; mild anti-inflammatory action	Modulates inflammatory response; reduces oxidative burden	Supports detoxification through improved microcirculation	Indirect anti-fibrotic role via anti-inflammatory effects
Phenolic acids (gallic, caffeic acid)	Scavenge ROS; reduce hepatic steatosis	Decrease oxidative stress markers; stabilize cell membranes	Neutralize reactive intermediates; reduce hepatocyte apoptosis	Reduce oxidative signaling involved in fibrogenesis[73]

5.2. Mechanisms of Hepatoprotective Action

Cocoa bioactives have intricate hepatoprotective mechanisms that include both direct antioxidant actions and intracellular signaling pathway modification. Reactive oxygen species (ROS) neutralization is one of the main ways. Lipid peroxidation chain reactions are stopped by cocoa flavanols, which give hydrogen atoms or electrons to free radicals such superoxide anions, hydroxyl radicals, and peroxynitrite. Malondialdehyde (MDA), an indication of lipid peroxidation, is markedly decreased by cocoa intake, according to experimental models of chemically induced hepatotoxicity (such as carbon tetrachloride and acetaminophen).[74]

In addition to direct scavenging, cocoa strengthens the body's natural antioxidant defenses. Research indicates that important enzyme antioxidants such as glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD) are upregulated. The Nrf2 (nuclear factor erythroid 2–related factor 2) signaling pathway is primarily activated to cause this action.[75] The polyphenols in cocoa encourage Nrf2 to go into the nucleus, where it attaches to antioxidant response elements (ARE) and triggers the transcription of phase II detoxifying and antioxidant genes, including NAD(P)H quinone oxidoreductase 1 (NQO1) and heme oxygenase-1 (HO-1). The liver's natural defenses against oxidative damage are reinforced by this process.[76]

By inhibiting redox-sensitive transcription factors, cocoa bioactives also have strong anti-inflammatory properties. Cocoa flavanols reduce the production of pro-inflammatory cytokines such TNF-α, IL-1β, and IL-6 in models of hepatic inflammation via blocking NF-κB activation. By reducing inflammatory signals, hepatocyte damage is limited and the development of steatosis into steatohepatitis is avoided. Cocoa also alters MAPK signaling pathways, which affects stress reactions and cellular survival.[77]

Another important method is mitochondrial protection. The mitochondrial electron transport chain is hampered by oxidative stress, which results in ATP depletion and increased ROS generation. Cocoa flavanols preserve cellular energy metabolism by enhancing mitochondrial biogenesis and maintaining membrane potential.[78] Increased glutathione levels further guard against oxidative damage to mitochondrial membranes. Cocoa lessens hepatocyte necrosis and apoptosis by maintaining mitochondrial activity.[79] By preventing the activation of hepatic stellate cells (HSCs), the primary cells responsible for generating collagen in chronic liver damage, cocoa exhibits anti-fibrotic effect in the context of liver fibrosis. Experimental investigations have shown a decrease in extracellular matrix deposition and a downregulation of transforming growth factor-beta (TGF-β) signaling. This implies a preventive function against the development of cirrhosis.[80]

5.3. Relevance in Metabolic and Toxic Liver Disorders

Insulin resistance and oxidative stress are key pathogenic factors in non-alcoholic fatty liver disease (NAFLD). Cocoa flavanols lower oxidative indicators, decrease hepatic fat buildup, and increase insulin sensitivity. Studies on animals reveal that supplementing with cocoa lowers the amount of liver triglycerides and improves histopathological scores. Cocoa reduces ethanol-induced ROS production and inflammatory reactions in alcoholic liver disease. Cocoa polyphenols improve antioxidant status and reduce hepatic enzyme leakage (ALT, AST) in drug-induced liver damage models.[81]

6. PRECLINICAL AND CLINICAL EVIDENCE FOR COCOA IN LIVER PROTECTION

A range of experimental models, including in vitro hepatocyte systems, animal toxicity models, and a few human clinical studies, have been used to assess cocoa's hepatoprotective capabilities. Although clinical translation is still developing, the data that is now available consistently supports antioxidant, anti-inflammatory, and mitochondrial-protective benefits.[82]

6.1. In Vitro Hepatocyte Models

HepG2 cells, primary rat hepatocytes, or human hepatocyte cultures subjected to oxidative or toxic stressors such hydrogen peroxide ($H2O_2$), ethanol, tert-butyl hydroperoxide, or acetaminophen metabolites are frequently used in in vitro investigations.[83] In these systems, cocoa flavanols, especially epicatechin and procyanidins, have shown notable cytoprotective benefits. Mechanistically, cocoa extracts lower lipid peroxidation, maintain mitochondrial membrane potential, and lessen the production of intracellular reactive oxygen species (ROS).[84] Models of hepatocyte damage caused by oxidative stress have shown reductions in malondialdehyde (MDA) levels of 30–60%. Additionally, via activating the Nrf2/ARE pathway, cocoa polyphenols increase endogenous antioxidant enzymes such as glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD). Furthermore, there has been evidence of NF-κB nuclear translocation reduction, which lowers the synthesis of pro-inflammatory mediators like TNF-α and IL-6. These results suggest that the bioactives in cocoa function as modulators of intracellular redox signaling as well as direct scavengers of radicals.[85]

6.2. Animal Models of Hepatic Injury

Stronger histological and molecular evidence for cocoa-mediated hepatoprotection can be found in animal models.

When compared to northern untreated toxic controls, cocoa supplementation dramatically lowers blood ALT and AST levels in carbon tetrachloride (CCl_4)-induced hepatotoxicity models, frequently by 25–50%. Histological examination usually reveals less inflammatory infiltration and centrilobular necrosis. While glutathione (GSH) levels are restored, lipid peroxidation indicators like MDA are significantly reduced.[86]

By lowering CYP2E1-associated ROS generation and enhancing mitochondrial activity, cocoa mitigates ethanol-mediated oxidative stress in models of alcohol-induced liver damage. Research shows a decrease in the expression of inflammatory cytokines and a decrease in the buildup of hepatic triglycerides.[87] Consistent results show that antioxidant enzyme activity is increased and mitochondrial integrity is maintained. Cocoa polyphenols limit glutathione depletion, prevent hepatocellular necrosis, and lessen the production of reactive metabolites in toxicity models caused by paracetamol (acetaminophen).[88]

There is a considerable decrease in apoptosis-related indicators like caspase-3 and serum biomarkers like ALT and AST.[89] A protective function against drug-induced liver damage (DILI) is supported by these findings. Cocoa has been demonstrated to reduce collagen deposition and α-SMA expression in fibrosis models, namely chronic CCl_4 exposure, suggesting suppression of hepatic stellate cell activation and fibrogenesis.[90]

6.3. Clinical Trials on Cocoa Supplementation

There are less human clinical data available, and they mostly concentrate on cardiovascular outcomes and metabolic syndrome, with a secondary analysis of biomarkers linked to the liver. Supplementing with cocoa flavanol (usually 200-900 mg/day) has been related to improvements in inflammatory profiles and decreases in oxidative stress indicators in people with obesity or insulin resistance, illnesses that are strongly connected to non-alcoholic fatty liver disease (NAFLD).[91]

In people with elevated baseline levels, several studies demonstrate moderate decreases in ALT and AST. Improvements in endothelial function and reductions in C-reactive protein (CRP) point to systemic anti-inflammatory advantages that might tangentially promote liver health. Large-scale, long-term clinical studies that target liver illnesses like ALD or NAFLD particularly are still few, nevertheless.[92]

6.4. Biomarkers Evaluated in Studies

Across experimental and clinical investigations, several biomarkers are consistently measured:

- Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) serve as primary indicators of hepatocellular injury. Cocoa supplementation frequently reduces these enzymes in toxic injury models.[93]
- Malondialdehyde (MDA) is widely used to assess lipid peroxidation and oxidative stress. Significant reductions in MDA levels support antioxidant efficacy.[94]
- C-reactive protein (CRP) reflects systemic inflammation. Decreases in CRP suggest anti-inflammatory potential, particularly relevant in NAFLD and metabolic liver disorders.
- Other commonly assessed parameters include glutathione (GSH), SOD, CAT, GPx activity, TNF-α, IL-6, and histological scoring of hepatic steatosis or fibrosis.[95]

6.5. Bioavailability and Pharmacokinetic Considerations

Even while cocoa polyphenols have potent antioxidant activity in vitro, their bioavailability poses a substantial translational barrier. In the small intestine, monomeric flavanols like epicatechin undergo phase II metabolism (glucuronidation, sulfation, and methylation) and are comparatively efficiently absorbed. After consumption, peak plasma concentrations usually happen 1-2 hours later.[96]

On the other hand, the gut microbiota substantially breaks down bigger procyanidins into smaller phenolic metabolites, which may have systemic effects, and they have limited direct absorption. Therefore, circulating metabolites rather than native chemicals may be more

important for biological action in vivo. Flavanol concentration is greatly influenced by processing techniques; alkalization, or "Dutch processing," considerably lowers polyphenol levels.[97]

The makeup of each person's gut bacteria, dosage, and dietary matrix all has an impact on pharmacokinetics and treatment results. Overall, despite the substantial preclinical evidence for cocoa's hepatoprotective potential, bioavailability issues, dosage variability, and research design heterogeneity continue to hinder clinical validation. Standardized flavanol-rich formulations, pharmacokinetic optimization, and carefully planned clinical studies aimed at certain liver diseases should be the main areas of future study.

7. CONCLUSION AND FUTURE PERSPECTIVES

The increasing amount of experimental data indicates that the bioactives obtained from Theobroma cacao use intricately linked molecular pathways to provide a variety of hepatoprotective actions. Epicatechin, catechin, and procyanidins are examples of cocoa flavanols that have dual roles as modulators of intracellular redox signaling and direct scavengers of free radicals. Mechanistically, these substances protect mitochondrial integrity, improve antioxidant enzymes (SOD, CAT, and GPx), restore glutathione homeostasis, and reduce lipid peroxidation. Their protective effect is mostly due to the activation of the Nrf2/ARE pathway and the reduction of NF-κB-mediated inflammatory signaling. Additionally, downregulating TGF-β-driven fibrogenesis and inhibiting hepatic stellate cell activation point to a possible involvement in halting the development of steatosis to fibrosis and cirrhosis.

Cocoa bioactives show promise as a treatment for a variety of liver conditions, including as NAFLD, alcoholic liver disease, drug-induced liver damage, and early-stage fibrosis. They are positioned as prospective supplemental nutraceutical agents due to their capacity to address oxidative stress, inflammation, mitochondrial dysfunction, and metabolic dysregulation. Crucially, the pleiotropic properties of cocoa enable the simultaneous regulation of several clinical checkpoints, which is beneficial in complex situations like metabolic liver disease. However, extract standardization must be carefully considered before being translated into therapeutic practice. Depending on how cocoa is grown, fermented, roasted, and alkalized, its polyphenol concentration varies greatly. To guarantee repeatability, dosage adjustment, and regulatory clarity, standardized flavanol-rich extracts with a specific epicatechin or total procyanidin concentration are necessary. Clinical outcome variability is likely to continue in the absence of such standardization.

Strategies for nanoformulation provide encouraging chances to get around restrictions on bioavailability. The solubility, stability, intestinal absorption, and targeted hepatic administration of cocoa polyphenols may all be improved by encapsulating them in solid lipid nanoparticles, liposomes, nanoparticles, or nanoemulsions. These methods may enhance therapeutic effectiveness, lower dose requirements, and improve pharmacokinetic characteristics. A proactive approach to optimizing clinical effect is the integration of nanotechnology with nutraceutical development. There are still large gaps in the clinical data, despite promising preclinical results. There aren't many large-scale, randomized, placebo-controlled studies that are especially developed to assess outcomes linked to the liver. Future studies should concentrate on standardized dosage schedules, long-term safety assessment, well-characterized patient groups (such as biopsy-confirmed NAFLD), and study of validated biomarkers such inflammatory cytokines, ALT, AST, MDA, and imaging-based fibrosis scores.

Furthermore, research on metabolite-mediated effects and interactions with the gut microbiome may provide further light on hepatic and systemic pathways.

To sum up, Theobroma cacao's cocoa bioactives offer a mechanistically validated and scientifically promising nutraceutical strategy for liver protection. Developments in formulation science, extract standardization, and thorough clinical validation might make cocoa-derived chemicals useful supplements for the treatment and prevention of liver diseases brought on by oxidative stress.

REFERENCES

1. Oracz J, Nebesny E, Zyzelewicz D, Budryn G, Luzak B. Bioavailability and metabolism of selected cocoa bioactive compounds: A comprehensive review. Critical reviews in food science and nutrition, 2020 Jul 3; 60(12): 1947-85.
2. Munteanu C, Schwartz B. The effect of bioactive aliment compounds and micronutrients on non-alcoholic fatty liver disease. Antioxidants, 2023 Apr 10; 12(4): 903.
3. Jaramillo Flores ME. Cocoa flavanols: Natural agents with attenuating effects on metabolic syndrome risk factors. Nutrients, 2019 Mar 30; 11(4): 751.
4. Mellor DD, Naumovski N. Effect of cocoa in diabetes: the potential of the pancreas and liver as key target organs, more than an antioxidant effect?. International Journal of Food Science and Technology, 2016 Apr; 51(4): 829-41.
5. Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, Feng Y. The role of oxidative stress and antioxidants in liver diseases. International journal of molecular sciences, 2015 Nov 2; 16(11): 26087-124.
6. Scapagnini G, Davinelli S, Di Renzo L, De Lorenzo A, Olarte HH, Micali G, Cicero AF, Gonzalez S. Cocoa bioactive compounds: significance and

potential for the maintenance of skin health. Nutrients, 2014 Aug; 6(8): 3202-13.
7. Qader M, Xu J, Yang Y, Liu Y, Cao S. Natural Nrf2 activators from juices, wines, coffee, and cocoa. Beverages, 2020 Dec 1; 6(4): 68.
8. Tušek K, Valinger D, Jurina T, Sokač Cvetnić T, Gajdoš Kljusurić J, Benković M. Bioactives in cocoa: Novel findings, health benefits, and extraction techniques. Separations, 2024 Apr 19; 11(4): 128.
9. Sun M, Gu Y, Glisan SL, Lambert JD. Dietary cocoa ameliorates non-alcoholic fatty liver disease and increases markers of antioxidant response and mitochondrial biogenesis in high fat-fed mice. The Journal of nutritional biochemistry, 2021 Jun 1; 92: 108618.
10. Muscolo A, Mariateresa O, Giulio T, Mariateresa R. Oxidative stress: the role of antioxidant phytochemicals in the prevention and treatment of diseases. International journal of molecular sciences, 2024 Mar 13; 25(6): 3264.
11. Martín MÁ, Serrano AB, Ramos S, Pulido MI, Bravo L, Goya L. Cocoa flavonoids up-regulate antioxidant enzyme activity via the ERK1/2 pathway to protect against oxidative stress-induced apoptosis in HepG2 cells. The Journal of nutritional biochemistry, 2010 Mar 1; 21(3): 196-205.
12. Shair RM, Maskat MY, Ayob MK, Kasran R. Protective effect of cocoa extract on ethanol induced liver injury in sprague-dawley rats. Sains Malaysiana, 2020 Jan 1; 49(1): 93-101.
13. Giacometti J, Muhvić D, Pavletić A, Đudarić L. Cocoa polyphenols exhibit antioxidant, anti-inflammatory, anticancerogenic, and anti-necrotic activity in carbon tetrachloride-intoxicated mice. Journal of Functional Foods, 2016 May 1; 23: 177-87.
14. F. Nabavi S, Sureda A, Daglia M, Rezaei P, M. Nabavi S. Anti-oxidative polyphenolic compounds of cocoa. Current Pharmaceutical Biotechnology, 2015 Oct 1; 16(10): 891-901.
15. Marcucci G, Domazetovic V, Nediani C, Ruzzolini J, Favre C, Brandi ML. Oxidative stress and natural antioxidants in osteoporosis: novel preventive and therapeutic approaches. Antioxidants, 2023 Feb; 12(2): 373.
16. Sun M. Dietary Cocoa (Theobroma Cacao) Supplementation Improves Obesity-related Fatty Liver Disease in Mice.
17. Andújar I, Recio MC, Giner RM, Ríos J. Cocoa polyphenols and their potential benefits for human health. Oxidative medicine and cellular longevity, 2012; 2012(1): 906252.
18. Goya L, Kongor JE, de Pascual-Teresa S. From cocoa to chocolate: effect of processing on flavanols and methylxanthines and their mechanisms of action. International Journal of Molecular Sciences, 2022 Nov 18; 23(22): 14365.
19. Cordero-Herrera I, Martín MÁ, Goya L, Ramos S. Cocoa intake ameliorates hepatic oxidative stress in young Zucker diabetic fatty rats. Food research international, 2015 Mar 1; 69: 194-201.
20. Ali F, Ismail A, Kersten S. Molecular mechanisms underlying the potential antiobesity- related diseases effect of cocoa polyphenols. Molecular nutrition & food research, 2014 Jan; 58(1): 33-48.
21. Sarriá B, Martínez-López S, Sierra-Cinos JL, Garcia-Diz L, Goya L, Mateos R, Bravo L. Effects of bioactive constituents in functional cocoa products on cardiovascular health in humans. Food Chemistry, 2015 May 1; 174: 214-8.
22. Ramos S, Martín MA, Goya L. Effects of cocoa antioxidants in type 2 diabetes mellitus. Antioxidants, 2017 Oct 31; 6(4): 84.
23. Dama A, Shpati K, Daliu P, Dumur S, Gorica E, Santini A. Targeting metabolic diseases: the role of nutraceuticals in modulating oxidative stress and inflammation. Nutrients, 2024 Feb 10; 16(4): 507.
24. Arrigoni R, Cammarota F, Porro R, Cantore S, Dioguardi M, Cazzolla AP, De Leonardis F, Polimeno L, Zerman N, Di Cosola M, Mastrangelo F. Natural bioactive compounds against oxidative stress: dietary polyphenols strike back. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders), 2023 May 1; 23(6): 764-76.
25. Martins Gregório B, Benchimol De Souza D, Amorim de Morais Nascimento F, Matta L, Fernandes-Santos C. The potential role of antioxidants in metabolic syndrome. Current pharmaceutical design, 2016 Feb 1; 22(7): 859-69.
26. Akbari B, Baghaei- Yazdi N, Bahmaie M, Mahdavi Abhari F. The role of plant- derived natural antioxidants in reduction of oxidative stress. BioFactors, 2022 May; 48(3): 611-33.
27. Arlorio M, Bottini C, Travaglia F, Locatelli M, Bordiga M, Coisson JD, Martelli A, Tessitore L. Protective activity of Theobroma cacao L. phenolic extract on AML12 and MLP29 liver cells by preventing apoptosis and inducing autophagy. Journal of agricultural and food chemistry, 2009 Nov 25; 57(22): 10612-8.
28. Davinelli S, Corbi G, Righetti S, Sears B, Olarte HH, Grassi D, Scapagnini G. Cardioprotection by cocoa polyphenols and ω-3 fatty acids: a disease-prevention perspective on aging-associated cardiovascular risk. Journal of Medicinal Food, 2018 Oct; 21(10): 1060-9.
29. Allgrove JE, Davison G. Chocolate/cocoa polyphenols and oxidative stress. InPolyphenols: Mechanisms of Action in Human Health and Disease, 2018 Jan 1; (207-219). Academic Press.
30. Keen CL, Holt RR, Oteiza PI, Fraga CG, Schmitz HH. Cocoa antioxidants and cardiovascular health. The American journal of clinical nutrition, 2005 Jan 1; 81(1): 298S-303S.
31. Imam SS. The future of non-invasive ways to treat cancer. Int J Pharm Sci & Res., 2021; 12(8): 4684-96.

32. Imam SS, Agarwal S. A Pragmatic Approach To Treat Lung Cancer Through Loading Theaflavin - 3,3'-Digallate And Epigallocatechin Gallate In Spanlastic. Asian J Pharm Clin Res., 2021 Nov 7; 14(11): 1-8.
33. Imam SS, Imam ST, Mdwasifathar, Kumar R, Ammar MY. Interaction Between Ace2 And Sars-Cov2, And Use Of EGCG And Theaflavin To Treat Covid 19 In Initial Phases. International Journal of Current Pharmaceutical Research, 2022 Mar; 14(2): 5-10.
34. Imam SS, Sharma R. Natural compounds promising way to treat Lung Cancer. International Journal of Pharmaceutical Research and Applications, 2023; 8(2): 552-558.
35. Imam SS, Sharma S, Kumari D, Khan S, Pathak P, Katiyar D. An Expedient Approach to Treat Asthma through Non-Steroidal, Natural Transferosomes Aerosol System. Innovare journal of medical sciences, 2022; 10(6): 7-11.
36. Imam SS, Imam ST, Agarwal S, Kumar R, Ammar MY, Athar MW, Akthar A. Lung Cancer Therapy Using Naturally Occurring Products and Nanotechnology. Innovare journal of medical sciences, 2022; 10(4): 1-5.
37. Imam ST, Imam SS. The Cream which relieves the pain of Menstrual cramps without interfering with the Hormones or Period Cycle. Research Journal of Pharmacy and Technology, 2023; 16(3): 1239-6.
38. Imam SS. Topical Formulation Constituted with Transferosomes for the Treatment Of Non-Melanoma Skin Cancer. Asian J Pharm Clin Res., 2023 May 7; 16(5): 27-32.
39. IMAM SS. NANOPARTICLES: THE FUTURE OF DRUG DELIVERY. Int J Curr Pharm Sci., 2023 Nov. 15; 15(6): 8-15.
40. Imam SS, Mehdi S, Mansuri A. A COMPREHENSIVE REVIEW ON THE PHARMACOLOGICAL POTENTIAL OF RED GINSENG OIL, TEA TREE OIL AND HEMP SEED OIL. European Journal of Biomedical., 2024; 11(4): 167-77.
41. Imam SS. Sublingual Tablets Amalgamated with Nano-particles and natural products to treat Oral Cancer, 2024; 17(5): 2056-62.
42. Imam SS, Mehdi S. Factors Affecting Pharmaceutical Pricing In India. INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES, 2024; 2(4): 1367-1384. DOI: 10.5281/zenodo.11314004.
43. Mehdi S, Tabrez UZ, Imam SS. Management of Green Pharmaceuticals. International Journal of Pharmaceutical Sciences And Research, 2024; 15(7): 1951-1962. DOI: 10.13040/IJPSR.0975-8232.15(7).1951-62.
44. Imam SS. EVALUATING THE IMPACT OF US TARIFFS AND EVOLVING GLOBAL TRADE POLICIES ON PHARMACEUTICAL PRICING, MARKET PENETRATION, AND THE SUPPLY OF GENERIC MEDICINES FROM INDIA TO THE WORLD. Journal of Pharmacoeconomics and Pharmaceutical Management, 2025 Nov 7; 11(2): 27-34.
45. Imam SS. Pharmaceutical Marketing Management in India. Journal of Pharmacoeconomics and Pharmaceutical Management, 2024 Oct 23; 10(2): 37-48.
46. Żyżelewicz D, Zakłos-Szyda M, Juśkiewicz J, Bojczuk M, Oracz J, Budryn G, Miśkiewicz K, Krysiak W, Zduńczyk Z, Jurgoński A. Cocoa bean (Theobroma cacao L.) phenolic extracts as PTP1B inhibitors, hepatic HepG2 and pancreatic β-TC3 cell cytoprotective agents and their influence on oxidative stress in rats. Food Research International, 2016 Nov 1; 89: 946-57.
47. Hammond GN. *Ameliorative Effect of Natural Cocoa on Hepatic Injury Caused by Overdose of Paracetamol in Rats* (Doctoral dissertation, University of Ghana).
48. Jalil AM, Ismail A. Polyphenols in cocoa and cocoa products: is there a link between antioxidant properties and health?. Molecules, 2008 Sep 16; 13(9): 2190-219.
49. Ruvira S, Rodríguez-Rodríguez P, Ramiro-Cortijo D, Martín-Trueba M, Martín-Cabrejas MA, Arribas SM. Cocoa shell extract reduces blood pressure in aged hypertensive rats via the cardiovascular upregulation of endothelial nitric oxide synthase and nuclear factor (erythroid-derived 2)-like 2 protein expression. Antioxidants, 2023 Aug 31; 12(9): 1698.
50. Khan N, Khymenets O, Urpí-Sardà M, Tulipani S, Garcia-Aloy M, Monagas M, Mora-Cubillos X, Llorach R, Andres-Lacueva C. Cocoa polyphenols and inflammatory markers of cardiovascular disease. Nutrients, 2014 Feb 21; 6(2): 844-80.
51. Rebollo-Hernanz M, Aguilera Y, Martin-Cabrejas MA, Gonzalez de Mejia E. Phytochemicals from the cocoa shell modulate mitochondrial function, lipid and glucose metabolism in hepatocytes via activation of FGF21/ERK, AKT, and mTOR pathways. Antioxidants, 2022 Jan 8; 11(1): 136.
52. Zhao JW, Zhao WY, Zhao M, Yu L. Functional foods and bioactive compounds: A comprehensive review on their role in mitigating drug-induced liver injury. Frontiers in Nutrition, 2025 May 21; 11: 1499697.
53. Allgrove J, Davison G. Dark chocolate/cocoa polyphenols and oxidative stress. InPolyphenols in human health and disease, 2014 Jan 1; (241-251). Academic Press.
54. Leal-Mercado L, Panduro A, José-Abrego A, Roman S. Genome-based Mexican diet bioactives target molecular pathways in HBV, HCV, and MASLD: a bioinformatic approach for liver disease prevention. International Journal of Molecular Sciences, 2025 Sep 15; 26(18): 8977.
55. Sharma P, Nandave M, Nandave D, Yadav S, Vargas-De-La-Cruz C, Singh S, Tandon R, Ramniwas S, Behl T. Reactive oxygen species (ROS)-mediated oxidative stress in chronic liver

diseases and its mitigation by medicinal plants. American Journal of Translational Research, 2023 Nov 15; 15(11): 6321.
56. Miltonprabu S, Tomczyk M, Skalicka-Woźniak K, Rastrelli L, Daglia M, Nabavi SF, Alavian SM, Nabavi SM. Hepatoprotective effect of quercetin: From chemistry to medicine. Food and Chemical Toxicology, 2017 Oct 1; 108: 365-74.
57. Fernández-Tomé S, Ramos S, Cordero-Herrera I, Recio I, Goya L, Hernández-Ledesma B. In vitro chemo-protective effect of bioactive peptide lunasin against oxidative stress in human HepG2 cells. Food Research International, 2014 Aug 1; 62: 793-800.
58. Kim HI, Park J. Natural Antioxidants in Obesity and Related Diseases. Antioxidants, 2023 Nov 5; 12(11): 1966.
59. Goya L, Martín MÁ, Sarriá B, Ramos S, Mateos R, Bravo L. Effect of cocoa and its flavonoids on biomarkers of inflammation: studies of cell culture, animals and humans. Nutrients, 2016 Apr 9; 8(4): 212.
60. Xu Y, Tang G, Zhang C, Wang N, Feng Y. Gallic acid and diabetes mellitus: Its association with oxidative stress. Molecules, 2021 Nov 24; 26(23): 7115.
61. Gabriele M, Pucci L. Diet bioactive compounds: implications for oxidative stress and inflammation in the vascular system. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders), 2017 Dec 1; 17(4): 264-75.
62. Lee CC, Fan H, Tsopmo A, Regenstein JM, Ashaolu TJ. Plant-based antioxidant peptides: impact on oxidative stress and gut microbiota. Critical Reviews in Food Science and Nutrition, 2025 Dec 1; 65(32): 8006-29.
63. Rodríguez- Ramiro I, Ramos S, López- Oliva E, Agis- Torres A, Gómez- Juaristi M, Mateos R, Bravo L, Goya L, Martín MÁ. Cocoa- rich diet prevents azoxymethane- induced colonic preneoplastic lesions in rats by restraining oxidative stress and cell proliferation and inducing apoptosis. Molecular nutrition & food research, 2011 Dec; 55(12): 1895-9.
64. Oyovwi MO, Chijiokwu EA, Ben-Azu B, Atere AD, Joseph UG, Ogbutor UG, Udi OA. Potential roles of natural antioxidants in modulating neurodegenerative disease pathways. Molecular Neurobiology, 2025 Aug; 62(8): 10367-97.
65. Chandrasekara A, Shahidi F. Herbal beverages: Bioactive compounds and their role in disease risk reduction-A review. Journal of traditional and complementary medicine, 2018 Oct 1; 8(4): 451-8.
66. Aruoma OI. Methodological considerations for characterizing potential antioxidant actions of bioactive components in plant foods. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2003 Feb 1; 523: 9-20.
67. Balakina A, Sidorova Y, Petrov N, Shipelin V. Food minor bioactive compounds of polyphenolic and polyprenolic nature are promising agents for the prevention and therapy of non-alcoholic fatty liver disease. Molecules, 2025 Sep 18; 30(18): 3791.
68. Rahaman MM, Hossain R, Herrera- Bravo J, Islam MT, Atolani O, Adeyemi OS, Owolodun OA, Kambizi L, Daştan SD, Calina D, Sharifi- Rad J. Natural antioxidants from some fruits, seeds, foods, natural products, and associated health benefits: An update. Food science & nutrition, 2023 Apr; 11(4): 1657-70.
69. Xu J, Shen J, Yuan R, Jia B, Zhang Y, Wang S, Zhang Y, Liu M, Wang T. Mitochondrial targeting therapeutics: promising role of natural products in non-alcoholic fatty liver disease. Frontiers in pharmacology, 2021 Dec 23; 12: 796207.
70. Tüğen A, Buruleanu CL. The role of plant-derived bioactive compounds in mitigating oxidative stress. Foods, 2025 Dec 30; 15(1): 108.
71. Riaz Rajoka MS, Thirumdas R, Mehwish HM, Umair M, Khurshid M, Hayat HF, Phimolsiripol Y, Pallarés N, Martí-Quijal FJ, Barba FJ. Role of food antioxidants in modulating gut microbial communities: Novel understandings in intestinal oxidative stress damage and their impact on host health. Antioxidants, 2021 Sep 30; 10(10): 1563.
72. Rodriguez-Ramiro I, Vauzour D, Minihane AM. Polyphenols and non-alcoholic fatty liver disease: impact and mechanisms. Proceedings of the nutrition society, 2016 Feb; 75(1): 47-60.
73. Ali MY, Sina AA, Khandker SS, Neesa L, Tanvir EM, Kabir A, Khalil MI, Gan SH. Nutritional composition and bioactive compounds in tomatoes and their impact on human health and disease: A review. Foods, 2020 Dec 26; 10(1): 45.
74. Sahoo DK, Heilmann RM, Paital B, Patel A, Yadav VK, Wong D, Jergens AE. Oxidative stress, hormones, and effects of natural antioxidants on intestinal inflammation in inflammatory bowel disease. Frontiers in endocrinology, 2023 Aug 28; 14: 1217165.
75. Patel J, Roy H, Chintamaneni PK, Patel R, Bohara R. Advanced strategies in enhancing the hepatoprotective efficacy of natural products: integrating nanotechnology, genomics, and mechanistic insights. ACS Biomaterials Science & Engineering, 2025 Apr 11; 11(5): 2528-49.
76. Aktaş E, Hanağası HA, Özgentürk NÖ. Levodopa and Plant- Derived Bioactive Compounds in Parkinson's Disease: Mechanisms, Efficacy, and Future Perspectives. CNS Neuroscience & Therapeutics, 2025 Aug; 31(8): e70540.
77. Rebollo- Hernanz M, Cañas S, Braojos C, Cano- Muñoz P, Martín- Cabrejas MA. Cocoa shell: Source of novel bioactive ingredients for the prevention of cardiometabolic diseases. Molecular Mechanisms of Functional Food, 2022 Oct 13: 485-519.
78. Chu CC, Nyam KL. Application of seed oils and its bioactive compounds in sunscreen formulations.

Journal of the American Oil Chemists' Society, 2021 Jul; 98(7): 713-26.
79. Noce A, Di Lauro M, Di Daniele F, Pietroboni Zaitseva A, Marrone G, Borboni P, Di Daniele N. Natural bioactive compounds useful in clinical management of metabolic syndrome. Nutrients, 2021 Feb 16; 13(2): 630.
80. Altanam SY, Darwish N, Bakillah A. Exploring the Interplay of antioxidants, inflammation, and oxidative stress: Mechanisms, therapeutic potential, and clinical implications. Diseases, 2025 Sep 22; 13(9): 309.
81. Xiao J, Bai W. Bioactive phytochemicals. Critical reviews in food science and nutrition, 2019 Mar 26; 59(6): 827-9.
82. Savini I, Catani MV, Evangelista D, Gasperi V, Avigliano L. Obesity-associated oxidative stress: strategies finalized to improve redox state. International journal of molecular sciences, 2013 May 21; 14(5): 10497-538.
83. Wang Y. The interplay of exercise and polyphenols in cancer treatment: a focus on oxidative stress and antioxidant mechanisms. Phytotherapy Research, 2024 Jul; 38(7): 3459-88.
84. Girgih A, Ichoron N, Akinsola A, Igoli J. Free radicals and antioxidant quenching properties of plant phytochemicals in the management of oxidative stress. InPlant food phytochemicals and bioactive compounds in nutrition and health, 2024 Feb 27; (202-240). CRC Press.
85. Ashraf MV, Khan S, Misri S, Gaira KS, Rawat S, Rawat B, Khan MH, Shah AA, Asgher M, Ahmad S. High-altitude medicinal plants as promising source of phytochemical antioxidants to combat lifestyle-associated oxidative stress-induced disorders. Pharmaceuticals, 2024 Jul 23; 17(8): 975.
86. Saha P, Talukdar AD, Nath R, Sarker SD, Nahar L, Sahu J, Choudhury MD. Role of natural phenolics in hepatoprotection: a mechanistic review and analysis of regulatory network of associated genes. Frontiers in pharmacology, 2019 May 24; 10: 509.
87. Cicero AF, Fogacci F, Colletti A. Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach. Food & function, 2017; 8(6): 2076-88.
88. Rudrapal M, Khairnar SJ, Khan J, Dukhyil AB, Ansari MA, Alomary MN, Alshabrmi FM, Palai S, Deb PK, Devi R. Dietary polyphenols and their role in oxidative stress-induced human diseases: Insights into protective effects, antioxidant potentials and mechanism (s) of action. Frontiers in pharmacology, 2022 Feb 14; 13: 806470.
89. Flori L, Donnini S, Calderone V, Zinnai A, Taglieri I, Venturi F, Testai L. The nutraceutical value of olive oil and its bioactive constituents on the cardiovascular system. Focusing on main strategies to slow down its quality decay during production and storage. Nutrients, 2019 Aug 21; 11(9): 1962.
90. Teng YN. The Potential therapeutic applications of natural products in the oxidative stress-related MVA pathway: focus on HMGCR. Antioxidants, 2025 Aug 16; 14(8): 1001.
91. Pandurangan AK, Saadatdoust Z, Mohd. Esa N, Hamzah H, Ismail A. Dietary cocoa protects against colitis- associated cancer by activating the N rf2/K eap1 pathway. BioFactors, 2015 Jan 2; 41(1): 1-4.
92. López-Pedrouso M, Lorenzo JM, Franco D. Advances in natural antioxidants for food improvement. Antioxidants, 2022 Sep 16; 11(9): 1825.
93. Mittal S, Ashhar MU, Ahuja A, Ali J, Baboota S. Role of natural bioactives and their nanocarriers for overcoming oxidative stress induced cancer. Current Medicinal Chemistry, 2021 Nov 1; 28(36): 7477-512.
94. Sitarek P, Merecz-Sadowska A, Sikora J, Osicka W, Śpiewak I, Picot L, Kowalczyk T. Exploring the therapeutic potential of Theobroma cacao L.: insights from in vitro, in vivo, and nanoparticle studies on anti-inflammatory and anticancer effects. Antioxidants, 2024 Nov 11; 13(11): 1376.
95. Arellano-García L, Trepiana J, Martínez JA, Portillo MP, Milton-Laskibar I. Beneficial effects of viable and heat-inactivated Lactobacillus rhamnosus GG administration on oxidative stress and inflammation in diet-induced NAFLD in rats. Antioxidants, 2023 Mar 14; 12(3): 717.
96. Patil PP, Khanal P, Patil VS, Charla R, Harish DR, Patil BM, Roy S. Effect of Theobroma cacao L. on the efficacy and toxicity of doxorubicin in mice bearing ehrlich ascites carcinoma. Antioxidants. 2022 May 31;11(6):1094.
97. Alsarhan AA, Khwaldeh A, Shoiab AA, Al-Shdefat R, Alkhawaldeh AK, Yousef I, Aldamen N. Effect of curcumin and cacao extract on interleukin-6 expression on ribociclib-induced hepatotoxicity in rats. Tropical Journal of Pharmaceutical Research, 2024 Oct 8; 23(9): 1417-22.